Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Brigatinib vs Alectinib in ALK-positive NSCLC after Crizotinib
2018-001957-29Phase 3Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Brigatinib arm with Alectinib arm (2 arms). Primary endpoint: Progression-free survival (PFS). Started Aug 2018; status: completed.
02
Drugs
brigatinibalectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001957-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001957-29.